Bright Green Corporation has recently entered into a $250 million agreement with Dalsem Greenhouse Technologies BV for the construction of a new facility in rural Grants, New Mexico. This expansion project aims to enhance the company’s research, production and extraction capabilities for plant-based drugs and Active Pharmaceutical Ingredients (APIs) in the United States.
The proposed expansion will cover an area of 7 million square feet and will be built according to Dalsem’s specifications using modular construction methods. Additionally, Bright Green plans to power this facility with a 100-plus-megawatt solar field.
This significant investment is made possible by Bright Green obtaining regulatory approvals from both the DEA and State of New Mexico Board of Pharmacy for producing Schedule I and II controlled substances. The expanded facility will enable efficient production and manufacturing processes necessary for processing APIs as well as manufacturing generic prescription drugs.
This development marks an important milestone in Bright Green’s growth strategy towards becoming a leading player in pharmaceuticals industry.
